Výsledky vyhledávání

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study

Autor: Carol Yacik, Tara L. Frenkl, Michelle C. Fox, Robert Feldman, Yinna Wang

Publikováno v: Contraception. 94:362-365

Introduction We assessed performance and safety of the NuvaRing® Applicator. Methods We randomized women (18–45 years) to insert a placebo ring using the applicator or fingers-only and then vice versa. We assessed outcomes post-insertion and then

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb65391b46c6bfa55cbe04f29a6acdb9
https://doi.org/10.1016/j.contraception.2016.04.017

Zobrazit plný text záznamu

Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial

Autor: Guang Sheng Fan, Shuying Wu, Guoqin Wang, Yun Qin, Mulan Ren, Maya Marintcheva-Petrova, Wen Di, Christine McCrary Sisk, Carol Yacik, Qin Chang, Tjeerd Korver, Ping Su

Publikováno v: The European journal of contraceptionreproductive health care : the official journal of the European Society of Contraception. 21(4)

The aim of the study was to assess the efficacy and tolerability of the monthly vaginal ring (NuvaRing; 15 μg ethinylestradiol [EE] and 120 μg etonogestrel per day) compared with a monophasic (21/7) combined oral contraceptive (COC) containing 30 �

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2708a6be3fe6db72cbb6c6c94820a4
https://pubmed.ncbi.nlm.nih.gov/27339759

Zobrazit plný text záznamu

Plný text ve formátu HTML

Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled, exploratory study

Autor: Jonathan D. Adachi, Michael F.J. O’Mahony, Carol Yacik, Judith K. Evans, Rachid Massaad, R. Faraawi, Arun Nayar

Publikováno v: Clinical Therapeutics. 31:1747-1753

Background : The dissolution profiles of generic oral bisphosphonate alendronate (ALN) sodium for the treatment of postmenopausal osteoporosis differ by formulation, suggesting potential differences in the risk for upper gastrointestinal (GI) irritat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149841aaa3d51fd0b8c03e12e2e2e922
https://doi.org/10.1016/j.clinthera.2009.08.016

Zobrazit plný text záznamu

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

Autor: Dieter Felsenberg, Jorge Cannata Andia, Laurent Benhamou, Richard A. Petruschke, Luna Zaru, Andrea Rybak-Feglin, Jean-Yves Reginster, Silvano Adami, David J. Hosking, Matti Välimäki, Arthur C. Santora, Carol Yacik

Publikováno v: Current Medical Research and Opinion. 19:383-394

To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis.This was a 3-mont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e786cf2ddd51d0ddf30c22a1c17dd0ab
https://doi.org/10.1185/030079903125002009

Zobrazit plný text záznamu

An Open-Label, Randomized, Two-Period Crossover Study of the NuvaRing Applicator in Healthy Women [8N]

Autor: Michelle C. Fox, Tara L. Frenkl, Carol Yacik, Robert Feldman, Yinna Wang

Publikováno v: Obstetrics & Gynecology. 127:116S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c60875f0ea192e29a2a0022662d1fc7
https://doi.org/10.1097/01.aog.0000483477.23575.e2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání